The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Evaluation of avelumab first-line (1L) maintenance therapy and subsequent treatment (tx) in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) using a large claims database in Japan: JAVEMACS-D.
 
Takashi Kobayashi
Honoraria - Astellas Pharma; Bayer; Janssen; MSD
Consulting or Advisory Role - Astellas Pharma; Janssen
Speakers' Bureau - Astellas Pharma; Janssen
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Chugai Pharma
 
Hiroshi Kitamura
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Ferring; Janssen; Kissei Pharmaceutical; Merck; Pfizer; Takeda
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Merck KGaA; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Yuka Furukawa
No Relationships to Disclose
 
Anzu Kambe
Employment - Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany
 
Michihiro Shono
Employment - Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany
 
Takayuki Ito
Employment - Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Darmstadt, Germany
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Ferring; Janssen; MSD; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Janssen; Kissei Pharmaceutical; Kyorin; Merck; MSD; Nippon Kayaku; Nippon Shinyaku; Pfizer; Sanofi; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)